SETHOTOPE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SETHOTOPE (SETHOTOPE).
SETHOTOPE is a radiolabeled monoclonal antibody that binds to the prostate-specific membrane antigen (PSMA) on prostate cancer cells, delivering beta radiation (177Lu) to cause DNA damage and cell death.
| Metabolism | The radioactive component (177Lu) decays physically with a half-life of 6.65 days; the antibody component is catabolized to peptides and amino acids. No significant hepatic metabolism. |
| Excretion | Renal: 70% as unchanged drug; fecal: 25% as metabolites; biliary: 5% |
| Half-life | Terminal elimination half-life: 12 hours (range 10-14 h); clinically, dosing interval is 12-24 h to maintain therapeutic levels |
| Protein binding | 95% bound to albumin |
| Volume of Distribution | Vd: 2.5 L/kg (0.6-4.0 L/kg); indicates extensive tissue distribution |
| Bioavailability | Oral: 75% (range 60-90%); IM: 95% |
| Onset of Action | IV: 2-5 minutes; IM: 15-30 minutes; Oral: 45-60 minutes |
| Duration of Action | IV: 4-6 hours; IM: 6-8 hours; Oral: 8-12 hours; prolonged in hepatic impairment |
1.0 mg IV every 12 hours for 7 days.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 30-59 mL/min: 0.5 mg IV every 12 hours; GFR 15-29 mL/min: 0.5 mg IV every 24 hours; GFR <15 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 0.5 mg IV every 12 hours; Child-Pugh C: not recommended. |
| Pediatric use | 10-20 mg/kg IV every 12 hours; maximum 1.0 mg per dose. |
| Geriatric use | Start at 0.5 mg IV every 12 hours; titrate based on renal function and tolerability. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SETHOTOPE (SETHOTOPE).
| Breastfeeding | Breastfeeding is contraindicated during administration and for 24-48 hours post-procedure due to radioactive excretion. M/P ratio not established. After decay, resume breastfeeding following institutional guidelines. |
| Teratogenic Risk | SETHOTOPE is a radiopharmaceutical containing technetium-99m. Radiation exposure to the fetus increases risk of congenital anomalies and childhood cancer. First trimester: highest risk of teratogenesis; avoid unless benefit clearly outweighs risk. Second/third trimesters: risk of fetal radiation exposure; use only if essential diagnostic information cannot be obtained by other means. |
■ FDA Black Box Warning
Radiation exposure: Risk of myelosuppression, renal toxicity, and secondary malignancies due to radiation exposure. Handling and administration should follow radiation safety guidelines.
| Serious Effects |
Hypersensitivity to any component; pregnancy; severe renal impairment (CrCl <30 mL/min); pre-existing severe myelosuppression.
| Precautions | Myelosuppression (anemia, thrombocytopenia, neutropenia); renal toxicity; dry mouth; fatigue; nausea; risk of secondary malignancies; radiation precautions; pregnancy and lactation. |
Loading safety data…
| Fetal Monitoring | Monitor fetal radiation dose using dosimetry calculations. Document cumulative exposure. Perform pregnancy test prior to administration in women of childbearing potential. |
| Fertility Effects | No direct evidence of impaired fertility. However, radiation exposure to gonads may theoretically affect future fertility; minimize exposure. |